8-K/A: Ginkgo Bioworks Announces Q2 2024 Results and Restructuring Update

Ginkgo Bioworks reported a 30% decrease in revenue for Q2 2024, alongside an update on its restructuring plan aimed at achieving Adjusted EBITDA breakeven by the end of 2026.

Summary

• Ginkgo Bioworks reported a total revenue of $56 million for the second quarter of 2024, a 30% decrease compared to $81 million in the same period last year.
• This decline was primarily due to the expected reduction in K-12 testing within the Biosecurity segment.
• Cell Engineering revenue decreased by 20% to $36 million, driven by lower revenue from early-stage customers, partially offset by growth from large enterprise clients.
• Biosecurity revenue was $20 million with a gross profit margin of 41%.
• The company reported a loss from operations of $(223) million, which includes $38 million in stock-based compensation and $72 million in M&A and restructuring costs.
• Adjusted EBITDA was $(99) million, down from $(80) million in the prior year period.
• Ginkgo's cash and cash equivalents balance stood at $730 million at the end of the quarter.
• The company has commenced a reduction in force impacting 35% of its workforce as part of its restructuring plan.
• This restructuring is expected to yield over $85 million in annualized cost savings by mid-2025.
• Ginkgo has reaffirmed its full-year 2024 revenue guidance of $170-$190 million, with Cell Engineering revenue expected to be $120-140 million and Biosecurity revenue of at least $50 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant revenue declines and losses, but also includes positive developments like cost-cutting measures and new customer contracts. The overall sentiment is cautiously negative due to the financial challenges.

Positives

• Ginkgo is taking decisive action to reduce costs, aiming for Adjusted EBITDA breakeven by the end of 2026.
• The company has gained initial traction with its new Lab Data as a Service (LDaaS) offering, securing deals with a large cap tech company.
• Ginkgo added 18 new programs and customer contracts to the Cell Engineering platform in Q2 2024.
• The company delivered on a major technical milestone for a large pharmaceutical customer.
• Ginkgo announced a new collaboration with Syngenta Crop Protection.
• The company has a strong cash position of $730 million.
• Ginkgo is implementing significant non-people cost cutting measures, including rationalizing third-party costs and site consolidation.

Negatives

• Total revenue decreased by 30% year-over-year, primarily due to a decline in Biosecurity revenue.
• Cell Engineering revenue also saw a 20% decrease.
• The company reported a significant loss from operations of $(223) million.
• Adjusted EBITDA decreased to $(99) million.
• The company is undergoing a significant reduction in force, impacting 35% of its workforce.
• The company incurred $72 million in M&A and restructuring related costs, including asset impairments.

Risks

• The company's ability to realize cost savings from site consolidation is uncertain.
• There is volatility in the price of the company's securities due to various factors.
• The company faces risks related to downturns in demand for products using synthetic biology.
• There is uncertainty regarding the demand for passive monitoring programs and biosecurity services.
• Changes in the biosecurity industry could impact the company's business.
• The company faces potential legal proceedings.
• The company's ability to realize the expected benefits from its Foundry platform programs is not guaranteed.
• The product development or commercialization success of its customers is uncertain.
• The planned reduction in force could negatively impact the business if not managed effectively.

Future Outlook

Ginkgo reaffirms its full-year 2024 revenue guidance of $170-$190 million, with Cell Engineering revenue expected to be $120-140 million and Biosecurity revenue of at least $50 million. The company aims to reach Adjusted EBITDA breakeven by the end of 2026.

Management Comments

• Jason Kelly, co-founder and CEO of Ginkgo, stated that this past quarter was a quarter of focused execution.
• He also mentioned that the company is taking decisive action to reduce costs in order to reach Adjusted EBITDA breakeven by the end of 2026.
• Jason Kelly noted that the company has gained initial traction with its new lab data as a service (LDaaS) offering.

Industry Context

The announcement reflects a challenging period for synthetic biology companies, with Ginkgo facing revenue declines and restructuring efforts. The company's focus on cost reduction and new service offerings like LDaaS is indicative of a broader trend in the industry towards achieving profitability and sustainable growth. The collaboration with Syngenta also highlights the increasing interest in biological solutions in agriculture.

Comparison to Industry Standards

• Ginkgo's 30% revenue decline in Q2 2024 is significant and suggests a more challenging environment compared to some peers in the synthetic biology space, such as Amyris, which has also faced financial difficulties but has a different business model.
• The company's Adjusted EBITDA of $(99) million is a substantial loss, and while many biotech companies operate at a loss in early stages, the magnitude of Ginkgo's loss is notable compared to companies like Twist Bioscience, which has shown more moderate losses.
• The restructuring plan, including a 35% workforce reduction, is a drastic measure, similar to actions taken by other companies in the sector facing financial pressures, such as Zymergen, which ultimately filed for bankruptcy.
• Ginkgo's focus on LDaaS is a strategic move to diversify revenue streams, similar to how companies like Codexis are expanding their offerings beyond traditional enzyme engineering.
• The collaboration with Syngenta is a positive development, aligning with the trend of synthetic biology companies partnering with established players in various industries, similar to how companies like Intellia Therapeutics partner with pharmaceutical companies.

Stakeholder Impact

• Shareholders will be impacted by the decrease in revenue and the significant loss from operations.
• Employees will be impacted by the reduction in force.
• Customers may be impacted by the restructuring, but the company aims to continue delivering for them.
• Suppliers may be impacted by the company's cost-cutting measures.
• Creditors will be impacted by the company's financial performance.

Next Steps

• Ginkgo will continue to execute its restructuring plan, including further workforce reductions and facility consolidations.
• The company will focus on achieving Adjusted EBITDA breakeven by the end of 2026.
• Ginkgo will continue to develop and expand its LDaaS offering.
• The company will continue to work with its partners, including Syngenta, to develop new biological solutions.

Key Dates

Keywords

Ginkgo Bioworks, Synthetic Biology, Cell Engineering, Biosecurity, Restructuring, Cost Savings, Adjusted EBITDA, Revenue, Financial Results, LDaaS